- Home
- BMRN vs PPC Comparison
BMRN vs PPC Comparison
Compare BMRN & PPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRN
- PPC
- Stock Information
- Founded
- BMRN 1996
- PPC 1946
- Country
- BMRN United States
- PPC United States
- Employees
- BMRN N/A
- PPC N/A
- Industry
- BMRN Biotechnology: Pharmaceutical Preparations
- PPC Meat/Poultry/Fish
- Sector
- BMRN Health Care
- PPC Consumer Staples
- Exchange
- BMRN Nasdaq
- PPC Nasdaq
- Market Cap
- BMRN 12.1B
- PPC 12.5B
- IPO Year
- BMRN 1999
- PPC 1987
- Fundamental
- Price
- BMRN $54.97
- PPC $44.98
- Analyst Decision
- BMRN Buy
- PPC Hold
- Analyst Count
- BMRN 22
- PPC 6
- Target Price
- BMRN $93.43
- PPC $48.67
- AVG Volume (30 Days)
- BMRN 2.2M
- PPC 1.1M
- Earning Date
- BMRN 08-04-2025
- PPC 07-30-2025
- Dividend Yield
- BMRN N/A
- PPC 14.04%
- EPS Growth
- BMRN 152.82
- PPC 145.39
- EPS
- BMRN 2.71
- PPC 5.08
- Revenue
- BMRN $2,950,227,000.00
- PPC $17,979,366,000.00
- Revenue This Year
- BMRN $12.23
- PPC $2.74
- Revenue Next Year
- BMRN $9.99
- PPC $1.19
- P/E Ratio
- BMRN $20.28
- PPC $8.84
- Revenue Growth
- BMRN 19.36
- PPC 2.40
- 52 Week Low
- BMRN $52.93
- PPC $37.28
- 52 Week High
- BMRN $94.85
- PPC $57.16
- Technical
- Relative Strength Index (RSI)
- BMRN 40.74
- PPC 39.18
- Support Level
- BMRN $53.76
- PPC $44.04
- Resistance Level
- BMRN $56.25
- PPC $46.95
- Average True Range (ATR)
- BMRN 1.26
- PPC 1.11
- MACD
- BMRN 0.06
- PPC -0.03
- Stochastic Oscillator
- BMRN 28.09
- PPC 31.97
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
About PPC Pilgrim's Pride Corporation
Pilgrim's Pride is the second-largest poultry producer in the US (59% of 2024 sales), the UK (29% including other European sales), and Mexico (12%). Its UK and European arm also includes pork operations from the 2019 acquisition of Tulip. Pilgrim's sells to chain restaurants, food processors, food distributors, and retail chains. most of its US and Mexican sales come from fresh chicken, while prepared chicken and pork constitute most of its UK and European sales. JBS owns more than 80% of Pilgrim's Pride's outstanding shares, though it failed to acquire the remaining stake in 2021 after a special board committee deemed JBS' offer undervalued Pilgrim's Pride.